Literature DB >> 25077519

Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.

Daniel J Cameron1, Lorraine B Johnson, Elizabeth L Maloney.   

Abstract

Evidence-based guidelines for the management of patients with Lyme disease were developed by the International Lyme and Associated Diseases Society (ILADS). The guidelines address three clinical questions - the usefulness of antibiotic prophylaxis for known tick bites, the effectiveness of erythema migrans treatment and the role of antibiotic retreatment in patients with persistent manifestations of Lyme disease. Healthcare providers who evaluate and manage patients with Lyme disease are the intended users of the new ILADS guidelines, which replace those issued in 2004 (Exp Rev Anti-infect Ther 2004;2:S1-13). These clinical practice guidelines are intended to assist clinicians by presenting evidence-based treatment recommendations, which follow the Grading of Recommendations Assessment, Development and Evaluation system. ILADS guidelines are not intended to be the sole source of guidance in managing Lyme disease and they should not be viewed as a substitute for clinical judgment nor used to establish treatment protocols.

Entities:  

Keywords:  GRADE; Lyme disease; antibiotic prophylaxis; antibiotics; erythema migrans; persistent disease; treatment

Mesh:

Year:  2014        PMID: 25077519      PMCID: PMC4196523          DOI: 10.1586/14787210.2014.940900

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  200 in total

1.  Neurologic presentations in Lyme disease.

Authors:  P K Coyle; S E Schutzer
Journal:  Hosp Pract (Off Ed)       Date:  1991-11-15

2.  Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia.

Authors:  F Strle; R B Nadelman; J Cimperman; J Nowakowski; R N Picken; I Schwartz; V Maraspin; M E Aguero-Rosenfeld; S Varde; S Lotric-Furlan; G P Wormser
Journal:  Ann Intern Med       Date:  1999-01-05       Impact factor: 25.391

3.  Eucaryotic cells protect Borrelia burgdorferi from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycin.

Authors:  P Brouqui; S Badiaga; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

4.  Temporal changes in outer surface proteins A and C of the lyme disease-associated spirochete, Borrelia burgdorferi, during the chain of infection in ticks and mice.

Authors:  T G Schwan; J Piesman
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

5.  Treatment of the early manifestations of Lyme disease.

Authors:  A C Steere; G J Hutchinson; D W Rahn; L H Sigal; J E Craft; E T DeSanna; S E Malawista
Journal:  Ann Intern Med       Date:  1983-07       Impact factor: 25.391

Review 6.  The expanding Lyme Borrelia complex--clinical significance of genomic species?

Authors:  G Stanek; M Reiter
Journal:  Clin Microbiol Infect       Date:  2011-04       Impact factor: 8.067

Review 7.  Antibiotic retreatment of Lyme disease in patients with persistent symptoms: a biostatistical review of randomized, placebo-controlled, clinical trials.

Authors:  Allison K Delong; Barbara Blossom; Elizabeth L Maloney; Steven E Phillips
Journal:  Contemp Clin Trials       Date:  2012-08-19       Impact factor: 2.226

8.  Neurally mediated hypotension in systemic lupus erythematosus patients with fibromyalgia.

Authors:  S Tang; H Calkins; M Petri
Journal:  Rheumatology (Oxford)       Date:  2004-02-24       Impact factor: 7.580

9.  Doxycycline-mediated effects on persistent symptoms and systemic cytokine responses post-neuroborreliosis: a randomized, prospective, cross-over study.

Authors:  Johanna Sjöwall; Anna Ledel; Jan Ernerudh; Christina Ekerfelt; Pia Forsberg
Journal:  BMC Infect Dis       Date:  2012-08-10       Impact factor: 3.090

Review 10.  Antigenic variation in vector-borne pathogens.

Authors:  A G Barbour; B I Restrepo
Journal:  Emerg Infect Dis       Date:  2000 Sep-Oct       Impact factor: 6.883

View more
  52 in total

1.  The Lyme law.

Authors:  Elizabeth Zubek
Journal:  CMAJ       Date:  2015-04-21       Impact factor: 8.262

2.  Lyme Disease guidelines.

Authors:  Jane Bailey
Journal:  CMAJ       Date:  2016-07-12       Impact factor: 8.262

3.  Delineating Surface Epitopes of Lyme Disease Pathogen Targeted by Highly Protective Antibodies of New Zealand White Rabbits.

Authors:  Artem S Rogovskyy; Salvador Eugenio C Caoili; Yurij Ionov; Helen Piontkivska; Pavel Skums; Viachaslau Tsyvina; Alex Zelikovsky; Suryakant D Waghela
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

4.  New Zealand White Rabbits Effectively Clear Borrelia burgdorferi B31 despite the Bacterium's Functional vlsE Antigenic Variation System.

Authors:  Maliha Batool; Andrew E Hillhouse; Yurij Ionov; Kelli J Kochan; Fatemeh Mohebbi; George Stoica; David W Threadgill; Alex Zelikovsky; Suryakant D Waghela; Dominique J Wiener; Artem S Rogovskyy
Journal:  Infect Immun       Date:  2019-06-20       Impact factor: 3.441

Review 5.  Update on persistent symptoms associated with Lyme disease.

Authors:  Carlos R Oliveira; Eugene D Shapiro
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

Review 6.  Efficacy and Safety of Antibiotic Therapy in Early Cutaneous Lyme Borreliosis: A Network Meta-analysis.

Authors:  Gabriel Torbahn; Heidelore Hofmann; Gerta Rücker; Karin Bischoff; Michael H Freitag; Rick Dersch; Volker Fingerle; Edith Motschall; Joerg J Meerpohl; Christine Schmucker
Journal:  JAMA Dermatol       Date:  2018-11-01       Impact factor: 10.282

Review 7.  Lyme neuroborreliosis-epidemiology, diagnosis and management.

Authors:  Uwe Koedel; Volker Fingerle; Hans-Walter Pfister
Journal:  Nat Rev Neurol       Date:  2015-07-28       Impact factor: 42.937

Review 8.  Lyme Disease Frontiers: Reconciling Borrelia Biology and Clinical Conundrums.

Authors:  Vladimir V Bamm; Jordan T Ko; Iain L Mainprize; Victoria P Sanderson; Melanie K B Wills
Journal:  Pathogens       Date:  2019-12-16

9.  Hypersensitivity to tetracyclines: Skin testing, graded challenge, and desensitization regimens.

Authors:  Michelle C Maciag; Stephanie L Ward; Amy E O'Connell; Ana D Broyles
Journal:  Ann Allergy Asthma Immunol       Date:  2020-02-20       Impact factor: 6.347

Review 10.  Quantitative multiplexed strategies for human Lyme disease serological testing.

Authors:  Eunice Chou; Armond Minor; Nathaniel C Cady
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.